Balaxi Pharmaceuticals Q1 FY27 Results: Total Income ₹209.35 Cr, Net Profit ₹163.89 Cr
Balaxi Pharmaceuticals reported standalone Q1 FY27 total income of ₹209.35 crore and net profit of ₹163.89 crore. Consolidated figures show total income at ₹152.11 crore and net profit at ₹143.51 crore. EPS stood at ₹3.24 (standalone) and ₹2.84 (consolidated).
The announcement contains key financial results, including revenue and profit figures for the quarter, which are material information for investors and significantly impact the company's valuation and stock performance.
The company has reported a significant increase in net profit and total income for the quarter ended June 30, 2026, compared to the previous year, indicating positive financial performance.
Balaxi Pharmaceuticals Limited has announced its unaudited financial results for the quarter ended June 30, 2026. The company reported a total income of ₹209.35 crore for the standalone entity and ₹152.11 crore for the consolidated entity.
Net profit after tax for the standalone results stood at ₹163.89 crore, while the consolidated net profit after tax was ₹143.51 crore. The total comprehensive income for the standalone and consolidated entities were ₹4,328.76 crore and ₹4,308.85 crore, respectively.
Earnings per share (EPS) for the standalone entity were ₹3.24, and for the consolidated entity, it was ₹2.84. The company also provided total equity figures as of June 30, 2026, with standalone equity at ₹33,163.25 crore and consolidated equity at ₹4,308.85 crore. The financial results were published in "Business Standard" and "Nava Telangana" on August 6, 2026, and are also available on the company's website.
What to do with a filing like this
BALAXI PHARMACEUTICALS LIMITED filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by BALAXI PHARMACEUTICALS LIMITED. Read the original for the full detail.